Biomarker ID | 35 |
PMID | 12497024 |
Year | 2001 |
Biomarker | Triiodothyronine |
Biomarker Basis | Concentration Based (ng/dl) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in High Risk Group |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | High vs Low Risk Group |
Type of Biomarker | Prognostic |
Cohort | 68 men with localised prostate cncer were studied, low risk (n=24), moderate risk: (n=24), and high risk (n=20) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.013 |
Method Used | Chemoluminescent Assay |
Clinical | No |
Remarks | Low risk: serum PSA ≤10, stage≤T2a, or Gleason grade ≤ 6. These patients are treated with a radioactive implant; moderate risk: serum PSA 10-15 or Gleason 7 or ≤ T2b. These patients are treated with 3 months of combined hormonal therapy followed by an implant; high risk: Gleason > 7, tumor in seminal vesicle biopsy, serum PSA > 15 or stage T2c or T3. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | Triiodothyronine |